Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation processBusiness Overview Company manufactures pharmaceuticals and medicinal chemicals. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary). GTBL entered into Technical & Financial collaboration with Yuhan Corporation, South Korea, and...
Gujarat Themis Biosyn Limited's Fund-Raising Committee has approved the allotment of 2.12 crore equity shares to qualified institutional buyers (QIBs) via a Qualified Institutional Placement (QIP). The company successfully raised approximately Rs. 750 crore at an issue price of Rs. 354 per share. This capital infusion significantly increases the company's...
Gujarat Themis Biosyn (GTBL) is acquiring 100% of Japan's MicroBiopharm Japan (MBJ) for ~INR 1,300 Cr. MBJ, a pharma CDMO with ~INR 570 Cr FY26E revenue, enhances GTBL's strategy to become a tech-driven CDMO in precision fermentation and biotechnology.
Gujarat Themis Biosyn (GTBL) acquired Sanofi's portfolio of 13 anti-TB and anti-infective brands for €158 million cash. This move strengthens GTBL's global generics platform and expands its international footprint across 55+ countries, leveraging existing API capabilities.
Gujarat Themis Biosyn reported no re-lodgement requests for physical share transfers in December. This indicates smooth processing for investors regarding share-related activities, ensuring compliance with market requirements.
Gujarat Themis Biosyn (GTBL) reported zero requests for re-lodgement of physical share transfers for October and November. This indicates no recent activity under the special transfer window.
